GSK's Eyes Benlysta Expansion With First US FDA Lupus Nephritis Approval
Executive Summary
The new indication paves the way for Benlysta in a new patient population, as well as expansion in systemic lupus erythematosus, US specialty unit head Sheri Mullen said.